All entries in the Pharma sector, newest first. tag:eurotrack.ai,2026:en:en/sectors/pharma 2026-11-03T06:00:00Z Eurotrack tag:eurotrack.ai,2026:b8aaab14:en 2026-11-03T06:00:00Z

Basel-based contract manufacturer Lonza has signed an agreement to acquire five US development and manufacturing sites from Merck KGaA, with around 1,100 employees transferring to Lonza. The sites cover bioconjugates such as antibody-drug conjugates and viral vectors; Lonza goes from four to nine US sites and to more than 6,000 employees there. The enterprise value is in the low to mid triple-digit millions of Swiss francs (Lonza, ad hoc announcement, 3 November 2026). — Source: https://www.finanznachrichten.de/nachrichten-2026-11/70013589-adhoc-lonza-group-ag-lonza-signs-agreement-to-acquire-us-cdmo-network-from-merck-kgaa-darmstadt-germany-and-significantly-expands-its-us-presence-023.htm

tag:eurotrack.ai,2026:c3bd7008:en 2026-10-28T06:00:00Z

Swedish shell company Hunter Capital RTO 1 is taking over Danish biotech ResoTher Pharma in exchange for new shares, valuing ResoTher at SEK 225 million before capital raises. Existing shareholders will hold roughly 18%, and a general meeting still has to approve (Hunter Capital RTO 1 press release, 28.10.2026). — Source: https://news.cision.com/se/hunter-capital-rto-1-ab--publ-/r/hunter-capital-rto-1-signs-transaction-agreement-for-reverse-acquisition-of-resother-pharma,c4416286

tag:eurotrack.ai,2026:dc5d2388:en 2026-10-26T06:00:00Z

Tillotts Pharma signed a deal on 23 Oct 2026 to buy Haupt Pharma Wülfing, which has about 280 employees and makes Asacol among other products in Gronau. The price is confidential and closing needs regulatory approvals; Tillotts plans to invest about €23m in the site over the coming years (Tillotts via Presseportal, 26 Oct 2026). — Source: https://www.presseportal.de/pm/117622/6377798

tag:eurotrack.ai,2026:6153f9fe:en 2026-10-19T06:00:00Z

Merck KGaA is buying UK RNA specialist Silence Therapeutics for US$20 per depositary share in cash, 130% above the closing price on 16 October 2026; the deal is worth about US$1.3bn. Closing is expected in Q1 2027 (KSL citing Reuters, 19 October 2026; second source: Pulse 2.0, 19 October 2026). — Sources: https://www.ksl.com/article/51638103/germanys-merck-buys-silence-therapeutics-for-13-billion · https://pulse2.com/merck-to-acquire-silence-therapeutics-for-about-1-3-billion/

tag:eurotrack.ai,2026:fd44a238:en 2026-10-16T06:00:00Z

Synbiotic SE says in an ad-hoc notice that it will apply to the Münster local court to open insolvency proceedings. The company cites the persistently difficult cannabis market, financing not secured in time and the last shareholder meeting's refusal to approve new authorised capital. It expects a provisional insolvency administrator and, initially, continued operations; the notice gives no headcount (EQS ad-hoc, 16 Oct 2026). — Source: https://www.finanznachrichten.de/nachrichten-2026-10/69859545-eqs-adhoc-synbiotic-se-antrag-auf-eroeffnung-eines-insolvenzverfahrens-022.htm

tag:eurotrack.ai,2026:8765b553:en 2026-10-14T06:00:00Z

On 14 October 2026 GSK told a special works council about a restructuring in Belgium that would remove 1,217 jobs at its Walloon sites in Wavre, Rixensart and Gembloux, including 482 office and 735 managerial positions; blue-collar workers are exempt and the cuts are to run over two years. R&D, production and international support functions are affected; GSK employs about 8,500 people in Belgium. Unions had expected around 800 jobs; Setca and Solidaris criticised the plan on 16 October 2026 (VRT NWS, 14 Oct 2026; second source: La Dernière Heure, 16 Oct 2026). — Sources: https://www.vrt.be/vrtnws/en/2026/10/14/over-1-200-jobs-at-risk-at-vaccine-manufacturer-gsk/ · https://www.dhnet.be/dernieres-depeches/2026/10/16/gsk-les-licenciements-chez-gsk-consequence-dune-course-aux-surprofits-HZ4XVFHQ6BDG5DLLRMWKOGDYQI/

tag:eurotrack.ai,2026:7c161f06:en 2026-10-01T06:00:00Z

Fresenius has bought the remaining 45% of Madrid-based biosimilars maker mAbxience from Insud Pharma and Invim Corporativo and now owns the company outright; the price is up to €750m, of which €50m depends on site approvals. Signing and completion took place on 30 September 2026 with no regulatory approval required; Fresenius had acquired its 55% majority stake in August 2022, and mAbxience is part of Fresenius Kabi's Biopharma business (Fresenius via EQS, 01.10.2026). — Sources: https://www.webdisclosure.com/press-release/fresenius-se-co-kgaa-etr-fre-fresenius-acquires-remaining-45-of-mabxience-for-up-to-750-million-taking-full-ownership-of-its-biosimilars-platform-oY1qbs86akF · https://mabxience.com/fresenius-completes-acquisition-of-mabxience-creating-a-stronger-platform-for-future-portfolio-expansion/

tag:eurotrack.ai,2026:611215a1:en 2026-09-21T06:00:00Z

On 21 September 2026 Roche laid the foundation stone for the "Synthetic Molecules Facility" (Building 51) in Basel: a seven-storey production building for synthetic active pharmaceutical ingredients with highly automated, AI-supported processes; together with the modernisation of the neighbouring Building 50, the group is investing around CHF 790m, with completion planned for 2030. Around 200 employees are to work there; according to reports these are existing production jobs secured for the long term rather than new positions (swissinfo/Keystone-SDA, 21 Sep 2026; SRF). — Source: https://www.swissinfo.ch/ger/pharmariese-roche-legt-grundstein-f%C3%BCr-neuen-produktionsbau-in-basel/92092441

tag:eurotrack.ai,2026:320b100b:en 2026-09-21T06:00:00Z

On 21 September 2026 Aachen-based pharmaceutical company Grünenthal announced an agreement with Bayer AG to acquire the cancer medicine Stivarga® (regorafenib) for up to €375 million. The oral medicine is approved to treat certain advanced cancers — including metastatic colorectal cancer, gastrointestinal stromal tumours (GIST) and hepatocellular carcinoma — and is available in more than 90 markets. The acquisition is subject to customary closing conditions; Grünenthal has invested around €2.6 billion in M&A transactions since 2017. (Source: Grünenthal Group via Presseportal/ots, 21 Sep 2026) — Source: https://www.presseportal.de/pm/118252/6355664

tag:eurotrack.ai,2026:a4f77335:en 2026-09-21T06:00:00Z

Australian radiopharmaceuticals group Telix Pharmaceuticals is acquiring Munich-based ITM Isotope Technologies Munich SE; the upfront consideration is US$1.65 billion on a cash-free/debt-free basis, plus up to US$700 million on achievement of future regulatory approval and commercial sales milestones. After adjustments, ITM shareholders are expected to receive approximately US$1.25 billion in Telix shares at US$11.84 per share, released as Nasdaq ADRs after the respective escrow periods. ITM says it is the world's leading supplier of therapeutic radioisotopes (lutetium-177, actinium-225, terbium-161) and the only producer of globally scaled commercial-grade lutetium-177. (Source: ITM Isotope Technologies Munich SE press release, 21 Sep 2026) Update (30 October 2026): Telix has called its general meeting on the issue of up to 114.2 million upfront consideration shares for 1 December 2026; holders of over 93% of ITM shares have signed the agreement, so the 92.5% condition is met. The end date is 1 January 2027, with an automatic three-month extension if only regulatory approvals are outstanding (Telix, notice of meeting via SEC, 30 October 2026). — Sources: https://www.itm-radiopharma.com/news/press-releases/press-releases-detail/breaking-news-767/ · https://www.sec.gov/Archives/edgar/data/0002007191/000162828026068291/a20261030tlxnoticeofgene.htm

tag:eurotrack.ai,2026:dd829efe:en 2026-09-17T06:00:00Z

Recordati has opened a collective redundancy procedure at its Campoverde active-ingredient plant in Aprilia (Latina province) covering 55 of its 301 permanent staff, 7 white-collar and 48 blue-collar. The group cites smaller batch sizes for its in-house drug products, Chinese and Indian competition and a planned volume drop of about 21% (roughly 120 tonnes) in 2027–29; production is to be concentrated on fewer lines and department 337 closed. It rules out short-time work and solidarity contracts, and talks with the unions are under way at Unindustria in Latina (Latina Oggi, 17.09.2026). — Source: https://www.latinaoggi.eu/news/attualita/322417/recordati-al-via-la-procedura-di-licenziamento-collettivo-a-campoverde-55-esuberi.html

tag:eurotrack.ai,2026:77773a26:en 2026-09-14T06:00:00Z

Sanofi is handing 20 older medicines to Greifswald-based specialist Cheplapharm, including the anticoagulant Lovenox/Clexane outside the US, together with three plants: Csanyikvölgy near Miskolc in Hungary with about 400 staff, Jurong in Singapore with about 100 and Ploërmel in France with about 65. In return Sanofi receives a 26.4% stake in Cheplapharm; further financial details are still to come. Staff transfer with their existing contracts and collective agreements, and according to Világgazdaság with a three-year employment guarantee at Miskolc — no job cuts or closures are planned. The products start moving across in the first quarter of 2027, with the plants following after employee consultation and regulatory approvals; everything is due to be completed by the third quarter of 2027 (Bionity, 16 Sep 2026; announced on 14 Sep 2026 according to Világgazdaság, 1 Oct 2026). — Sources: https://www.bionity.com/en/news/1189829/sanofi-is-transferring-20-established-medicines-and-three-manufacturing-sites-to-cheplapharm.html · https://www.vg.hu/vilaggazdasag-magyar-gazdasag/2026/10/sanofi-gyar-eladas-miskolc-dolgozok-munka-nemet-francia

tag:eurotrack.ai,2026:75716136:en 2026-09-10T06:00:00Z

On 10 September 2026 GSK announced it will close its Dresden vaccine plant (founded 1911, 115 years of production) with around 650 employees by summer 2028 at the latest, citing globally declining demand and overcapacity; flu-vaccine production is to move to its Canadian site in Ste-Foy. Union IGBCE pledged resistance (Ärzteblatt, oiger.de, 10 Sep 2026). — Source: https://www.aerzteblatt.de/news/gsk-will-impfstoffwerk-dresden-schliessen-bc40c225-a1ee-405d-9847-975ca71b0fe4

tag:eurotrack.ai,2026:9a599980:en 2026-09-08T06:00:00Z

Generics maker Sandoz is building a biologic drug substance facility next to its recently opened biosimilar development centre in Ljubljana, with four single-use fed-batch bioreactors totalling 8,000 litres of capacity. The plant is due to start operating in 2029 and will serve both clinical and commercial manufacturing; it is part of the company's "Bio100" goal, and Sandoz has not given a number of new jobs (Sandoz, 08.09.2026). — Sources: https://live.deutsche-boerse.com/news/Sandoz-invests-in-new-drug-substance-facility-in-Ljubljana-Slovenia-to-expand-biosimilar-manufacturing-capacity-23f1196e-b606-4b6e-b51a-8c8e0c9dac11 · https://www.pharmazeutische-zeitung.de/neue-produktionsanlage-fuer-biosimilars-in-ljubljana-168200/

tag:eurotrack.ai,2026:23c27539:en 2026-09-04T06:00:00Z

Northway Biotech has opened the Baltics' first centre for cell therapy and personalised medicine at the BIO CITY III biotech park in Vilnius, with 3,500 m² and up to 20 GMP manufacturing lines; €61m was invested, funded from own resources and a loan from the development bank ILTE. About 100 specialists are to work there (Invest Lithuania, 4 September 2026). — Source: https://investlithuania.com/news/first-in-the-baltics-northway-biotech-opens-e61-million-cell-therapy-and-personalized-medicine-cdmo-in-vilnius/

tag:eurotrack.ai,2026:daa29821:en 2026-08-26T06:00:00Z

The CellforCure bioproduction site in Les Ulis (10,000 m², contract manufacturing of cell therapies), taken over by the Seqens group in 2023, will close for good for lack of customers and a buyer — by the end of September or October 2026 according to a company spokesperson; 115 employees are affected. Seqens had sought a buyer in April 2026; the cause is the collapse of the cell-therapy market since mid-2025 with cascading cancellations of biotech projects (L'Usine Nouvelle, 26 August 2026). — Source: https://www.usinenouvelle.com/sante-pharma/faute-de-clients-et-de-repreneur-lusine-cellforcure-des-ulis-site-historique-de-la-bioproduction-en-france-va-fermer-ses-portes.S3W3CGGZQNBENOE3CXMJK4G43Q.html

tag:eurotrack.ai,2026:3c4db44e:en 2026-08-17T06:00:00Z

Merck KGaA (Darmstadt) had agreed on 25 June 2026 to acquire US life-science company Bio-Techne (Minneapolis) for USD 73 per share (enterprise value around USD 11.3 billion / EUR 10 billion), strengthening its cell and gene therapy and precision diagnostics business. Germany's Federal Cartel Office cleared the merger on 17 August 2026 'after a short but intensive review'; clearances in other jurisdictions are still pending, with completion expected late 2026 or early 2027. The June announcement had not been recorded in the tracker; this entry is the authoritative one. Update (23 September 2026): The US waiting period under the Hart-Scott-Rodino Act expired on 18 September 2026, and Bio-Techne shareholders approved the takeover at a special meeting on 23 September 2026; completion is still expected in late 2026/early 2027 once the remaining clearances are in place (Bio-Techne release via BioSpace, 23 September 2026, https://www.biospace.com/press-releases/bio-techne-shareholders-approve-acquisition-by-merck-kgaa-darmstadt-germany). — Source: https://www.bundeskartellamt.de/SharedDocs/Meldung/DE/Pressemitteilungen/2026/08_17_26_BioTechne_MerckKGaA.html

tag:eurotrack.ai,2026:349d8f07:en 2026-08-11T06:00:00Z

Boehringer Ingelheim announced on 11 August 2026 that it has acquired Swiss biotech company Evax AG. Founded more than a decade ago as a spin-out of the University of Zurich, Evax develops therapeutic vaccines for horses, particularly against allergic skin diseases; the technology uses virus-like particles that prompt the immune system to produce neutralising antibodies. The deal builds on Boehringer's collaboration with, and subsequent 2024 acquisition of, Saiba Animal Health. Financial terms of the transaction were not disclosed. — Source: https://www.biospace.com/press-releases/boehringer-ingelheim-expands-equine-health-pipeline-with-acquisition-of-evax-ag

tag:eurotrack.ai,2026:fc7d4a03:en 2026-08-11T06:00:00Z

Italian pharmaceutical company Alfasigma signed a share purchase agreement with SEVER Life Sciences B.V. on 11 August 2026 for all shares in Netherlands-based Nordic Group B.V. (Nordic Pharma). Nordic Pharma has direct operations in 18 European countries as well as Canada and Japan, employs 265 people and generated around €190m in revenue in 2025; the main asset is its rheumatoid arthritis business around the methotrexate brand Nordimet, which complements Alfasigma's rheumatology portfolio (Jyseleca). Financial terms were not disclosed. — Source: https://www.biospace.com/press-releases/alfasigma-to-acquire-nordic-group-b-v-expanding-its-specialty-care-portfolio-and-presence-in-europe

tag:eurotrack.ai,2026:baeb18c8:en 2026-08-10T06:00:00Z

Radiopharmaceutical group Curium has completed the acquisition of Belgian company Abscint SA of Liège. The deal transfers global rights to ABS-011, a gallium-68-labelled PET diagnostic tracer targeting HER2 that is in a Phase 2b trial and aimed at breast and gastric cancers. The purchase price was not disclosed. — Source: https://www.biospace.com/press-releases/curium-acquires-abscint-sa-expanding-pet-radiodiagnostic-pipeline-in-oncology

tag:eurotrack.ai,2026:ded2d908:en 2026-08-02T06:00:00Z

Single-source report (Financial Times, 2 August 2026, picked up by CNBC): British-Swedish pharmaceutical group AstraZeneca is said to be in talks about a combination with US group Bristol Myers Squibb. The merged company would be valued at around $400bn, making it one of the world's largest pharmaceutical groups. Neither company commented. No binding agreement exists, and no second independent confirmation of the report was available when this entry was recorded. Update (5 August 2026): the report was denied. A person familiar with the matter told Reuters there is no deal between AstraZeneca and Bristol Myers Squibb, that “there never was a deal to be done” and that there are no discussions between the companies; a second person familiar with the matter confirmed that no active talks are under way. Neither group has issued a formal statement of its own (source: Pharmaceutical Executive citing Reuters, 5 August 2026). — Source: https://www.cnbc.com/2026/08/02/astrazeneca-and-bristol-myers-squibb-mull-400-billion-deal-report-.html

tag:eurotrack.ai,2026:a1422b7e:en 2026-07-29T06:00:00Z

According to the unions, Pfizer decided on 29 July 2026 to abandon its Catania site, which is more than 60 years old: 330 permanent staff and 40 fixed-term employees whose contracts will not be renewed are affected, out of 544 people at the plant. There is no plan to convert production; the company intends to sell the site and move parts of manufacturing — including the penicillin line — to China. The unions have called a strike (second source: CataniaToday). UPDATE (30 July 2026): Before the economic affairs committee of the Sicilian regional parliament (ARS), plant director Giuseppe Campobasso confirmed the group's position by video link — the site is to be given up with no reindustrialisation prospect. The previously announced strike had taken place on 22 July 2026, with rallies in Catania and outside the ministry in Rome (source: NewSicilia). Update (22 July 2026): The national crisis-table meeting at the Ministry of Enterprises and Made in Italy (Mimit) ended without result and was adjourned to 24 September 2026. Minister Adolfo Urso called on Pfizer to reverse its decision quickly and reiterated that the site must remain a strategic anchor of the Catania pharmaceutical cluster (source: LiveSicilia). Update (23 September 2026): The Mimit meeting scheduled for 24 September 2026 has been postponed and no new date is known. In a letter to the ministry and the company, the unions (Cgil, Cisl, Uil, Ugl) demand a suspension of the deadlines of the redundancy procedure launched on 2 July 2026, which affects 330 of 540 employees (source: Metropolis Più, 23 September 2026). Update (24 September 2026): The postponed crisis table at the Ministry of Enterprises and Made in Italy (Mimit) has been rescheduled for 6 October 2026; Minister Adolfo Urso plans to visit the Catania plant on 23 October 2026 (Hashtag Sicilia, 24 September 2026, https://www.hashtagsicilia.it/2026/09/24/vertenza-pfizer-fialc-cisal-bene-il-tavolo-al-mimit-lazienda-deve-restare-a-catania/). Update (13.10.2026): The Mimit has convened a new table with Pfizer, local institutions and unions for 20.10.2026 at 3 p.m. — the fourth meeting on the Catania site (La Sicilia, 13 Oct 2026). Update (20 October 2026): at the negotiating table at the industry ministry (Mimit), three international companies expressed interest in reindustrialising the Catania plant. Pfizer committed not to shut down the affected production lines beyond 31 October 2026 until the ministry has concluded talks with the interested parties (Il Sole 24 Ore Radiocor, 20 October 2026). — Sources: https://www.ansa.it/sicilia/notizie/2026/07/29/sindacati-pfizer-ha-deciso-di-abbandonare-il-sito-di-catania_19666a7b-61bd-4764-a064-6008a21a4aed.html · https://newsicilia.it/catania/cronaca/pfizer-lascia-catania-i-sindacati-dopo-tavolo-allars-sessantanni-cancellati-in-nome-del-profitto/1103282/ · https://livesicilia.it/pfizer-catania-vertenza-rinviata-al-24-settembre-il-mimit-punta-al-rilancio-del-sito/ · https://www.metropolispiu.it/2026/09/23/pfizer-riunione-al-mimic-rinviata-sindacati-allarmati/ · https://www.lasicilia.it/news/cronaca/3081448/urso-convoca-il-tavolo-per-pfizer-con-istituzioni-e-sindacati-al-centro-il-futuro-dello-stabilimento-di-catania.html · https://en.ilsole24ore.com/radiocor/nRC_20.10.2026_15.10_47410474

tag:eurotrack.ai,2026:6b5d5751:en 2026-07-20T06:00:00Z

Italian pharma group Alfasigma announced on 20 July — during a visit by Lazio regional president Francesco Rocca to its Pomezia site (over 500 employees) — an investment plan of over €40 million for 2026/2027: new plant and technologies, insourcing of processes and a strengthening of production lines (reported via the Italpress agency). — Source: https://www.italpress.com/farmaceutica-da-alfasigma-un-nuovo-piano-di-investimenti-per-il-polo-di-pomezia/

tag:eurotrack.ai,2026:8906419b:en 2026-07-19T06:00:00Z

On 19 July 2026 Samsung Biologics launched a public all-cash takeover offer for peptide contract manufacturer PolyPeptide Group (Swiss headquarters, SIX: PPGN): CHF 44.31 per share, around CHF 1.46bn in equity value and a 40% premium to the undisturbed price of CHF 31.65 (10 April 2026). The largest shareholder, holding roughly 55.65% of outstanding shares, has given an irrevocable tender undertaking and the independent board members unanimously recommend the offer. The minimum acceptance threshold is 66⅔% and completion is expected by the end of 2026. The European footprint at stake comprises PolyPeptide's plants in Sweden, Belgium and France plus its innovation centre in Strasbourg; the deal extends Samsung Biologics' CDMO portfolio beyond antibodies into peptide drugs. Figures per the company announcement. Update (31 August 2026): On 31 August 2026 Samsung Biologics published the offer prospectus through its Swiss subsidiary Samsung Peptide AG as formal offeror. The main acceptance period began on 15 September 2026 and is expected to end on 12 October 2026 at 4 p.m. Swiss time; the offer price (CHF 44.31 per share) and the minimum acceptance threshold (66⅔% on a fully diluted basis, excluding treasury shares) are unchanged (Samsung Biologics, 31 Aug 2026). Update (13 Oct 2026): According to the provisional interim result, about 87.59% of the capital had been tendered by the end of the main offer period on 12 October 2026; with parties acting in concert Samsung Peptide holds 87.92%. The definitive interim result is expected on 16 October 2026 (PolyPeptide, ad hoc announcement, 13 Oct 2026). Update (13.10.2026): If the offer is declared successful in the definitive interim result (expected 16.10.), the additional acceptance period runs from 19 to 30.10.2026, 4:00 p.m. Swiss time; regulatory approvals in certain jurisdictions, the removal of the transfer and voting restrictions and the election of Samsung's nominees to the board at an extraordinary general meeting on 26.10.2026 remain outstanding (PolyPeptide, ad hoc release, 13 Oct 2026). Update (19.10.2026): The definitive interim result of 16 Oct 2026 confirms 87.59% tendered (87.92% with concert parties); minimum acceptance reached, additional acceptance period 19–30 Oct 2026; the 13 Nov settlement is expected to be postponed, completion expected around end-2026 or Q1 2027, followed by squeeze-out and delisting (PolyPeptide, ad hoc announcement, 16 Oct 2026). Update (2 November 2026): after the additional acceptance period ended on 30 October 2026, Samsung Peptide and persons acting in concert hold 97.99% of PolyPeptide shares according to the provisional end result; 97.66% of the capital was tendered. The offer still depends on regulatory approvals in some jurisdictions, and the definitive end result is due on 5 November 2026 (PolyPeptide, ad hoc release, 2 November 2026). — Sources: https://www.prnewswire.com/news-releases/samsung-biologics-announces-all-cash-offer-to-acquire-polypeptide-accelerating-multi-modality-strategy-and-expanding-global-network-across-us-europe-and-india-302829249.html · https://www.finanznachrichten.de/nachrichten-2026-10/69818961-adhoc-polypeptide-group-provisional-interim-result-of-the-public-tender-offer-of-samsung-biologics-co-ltd-023.htm · https://www.webdisclosure.com/press-release/polypeptide-group-provisional-interim-result-of-the-public-tender-offer-of-samsung-biologics-co-ltd-Vd8rOdUJFKs · https://www.finanznachrichten.de/nachrichten-2026-11/70000926-adhoc-polypeptide-group-provisional-end-result-of-the-public-tender-offer-of-samsung-biologics-co-ltd-023.htm

tag:eurotrack.ai,2026:7f289e90:en 2026-07-15T06:00:00Z

UK pharma group GSK completed its acquisition of US oncology specialist Nuvalent on 15 July (equity value approx. $10.6bn, approx. $9.4bn net of cash). GSK gains three lung-cancer assets, two of them under FDA review (PDUFA dates September/November 2026). Source is the SEC 6-K filing; second source: Investing.com. — Source: https://www.sec.gov/Archives/edgar/data/0001131399/000165495426006663/a5060m.htm

tag:eurotrack.ai,2026:55c57092:en 2026-07-07T06:00:00Z

Pfizer is cutting 330 direct jobs at its Catania site, plus around 40 temporary workers. Plans include shutting down production lines (including penicillin) and a gradual withdrawal from the site, which has existed since 1959; the unions have announced strong mobilisation and a strike. Cross-reference: precursor to the Catania site exit decided on 29 July 2026 (closures entry); the figure of 370 affected is carried there and set to null here to avoid double counting. — Source: https://www.ansa.it/sicilia/notizie/2026/07/07/sindacati-mobilitazione-dura-contro-330-esuberi-alla-pfizer-di-catania_4244702f-8405-42f2-b4be-6f556f359516.html

tag:eurotrack.ai,2026:d892dbb6:en 2026-07-02T06:00:00Z

Novartis has opened a plant in Ljubljana for the aseptic filling of biological and RNA-based medicines into syringes and vials, and for their packaging. The investment, approved in 2021, will employ more than 300 specialists; the release does not say how many are new, and gives no investment amount (Novartis Slovenia, 2 Jul 2026). Update (2 July 2026): Novartis opened its new aseptic manufacturing plant in Ljubljana on 2 July 2026. (Novartis Slovenia, 2 July 2026) — Source: https://www.novartis.com/si-en/news/media-releases/novartis-v-ljubljani-odprl-nov-obrat-za-asepticno-proizvodnjo

tag:eurotrack.ai,2026:18332026:en 2026-06-01T06:00:00Z

The Swiss generics manufacturer is expanding its production capacities for biosimilars at the Toulouse site. Announced at the Choose France summit 2026. — Source: https://gazette-du-midi.fr/au-sommaire/entreprises/sandoz-150-meur-toulouse

tag:eurotrack.ai,2026:2e46194d:en 2026-06-01T06:00:00Z

Boehringer Ingelheim is investing around €500 mn by 2030 in research, development and production in the field of animal health at several French sites. — Source: https://en.media.businessfrance.fr/news/choose-france-2026-france-confirms-its-ability-to-attract-foreign-investment-c94e6-aba4d-1.html

tag:eurotrack.ai,2026:6a833e13:en 2026-05-22T06:00:00Z

CVC, already holding 46.8% of Recordati, has made a binding cash offer of €51.29 per share, about €10.7bn, together with GBL, ADIA unit Luxinva, Canadian pension fund CPPIB and chairman Andrea Recordati, aiming to delist the company; CVC had made a non-binding approach in March (pharmaphorum, 22 May 2026). Update (6 October 2026): the bidders raised the offer to €53 per share (Il Sole 24 Ore, 6 October 2026). — Sources: https://pharmaphorum.com/news/gbl-joins-cvc-eu107bn-takeover-bid-recordati · https://en.ilsole24ore.com/art/cvc-and-gbl-raise-their-bid-for-recordati-to-53-euros-per-share-AJbA2caB

tag:eurotrack.ai,2026:0d4ee9d1:en 2026-05-05T06:00:00Z

BioNTech is ending Covid vaccine production in Germany and cutting up to 1,860 jobs (around 22 percent). Those affected include Marburg (around 540), Idar-Oberstein (around 440) and around 820 jobs at the acquired company CureVac; expected savings of up to €500 mn per year from 2029. Update (28.09.2026): BioNTech found no buyers for its three German plants; they will close in stages – Tübingen at the end of 2027, Marburg in early 2028, Idar-Oberstein at the end of 2028 – affecting about 1,800 employees according to the company (ZDFheute, 28.09.2026). — Sources: https://www.onvista.de/news/2026/05-05-biontech-schliesst-deutsche-werke-und-streicht-1860-stellen-0-20-26508128 · https://www.zdfheute.de/wirtschaft/unternehmen/biontech-marburg-idar-oberstein-tuebingen-schliessung-100.html

tag:eurotrack.ai,2026:80d9b86d:en 2026-05-05T06:00:00Z

As part of the group restructuring, BioNTech is closing its Marburg production plant by the end of 2027; around 540 jobs are being cut. The background is the sharply declined demand for coronavirus vaccines. Cross-reference: the roughly 540 jobs are included in the up to 1,860 jobs of the group restructuring announced the same day (layoffs entry of 5 May 2026); the figure is carried there and set to null here to avoid double counting. Update (28.09.2026): The search for buyers failed; BioNTech confirmed the closure and now gives early 2028 as the end date for Marburg (Tübingen end of 2027, Idar-Oberstein end of 2028; about 1,800 employees in total), citing a difficult market and investment climate (ZDFheute, 28.09.2026). — Sources: https://www.wiwo.de/unternehmen/industrie/biontech-schliesst-standorte-und-baut-1860-stellen-ab/100222527.html · https://www.zdfheute.de/wirtschaft/unternehmen/biontech-marburg-idar-oberstein-tuebingen-schliessung-100.html

tag:eurotrack.ai,2026:281be517:en 2026-05-05T06:00:00Z

The Idar-Oberstein plant will also be closed by the end of 2027, with around 440 jobs affected. In Germany, besides the headquarters in Mainz, only the office locations in Berlin and Munich will remain. Cross-reference: the roughly 440 jobs are included in the up to 1,860 jobs of the group restructuring announced the same day (layoffs entry of 5 May 2026); the figure is carried there and set to null here to avoid double counting. Update (28.09.2026): The search for buyers failed; BioNTech confirmed the closure and now gives the end of 2028 as the end date for Idar-Oberstein (Tübingen end of 2027, Marburg early 2028; about 1,800 employees in total), citing a difficult market and investment climate (ZDFheute, 28.09.2026). — Sources: https://www.wiwo.de/unternehmen/industrie/biontech-schliesst-standorte-und-baut-1860-stellen-ab/100222527.html · https://www.zdfheute.de/wirtschaft/unternehmen/biontech-marburg-idar-oberstein-tuebingen-schliessung-100.html

tag:eurotrack.ai,2026:5f4415f1:en 2026-03-31T06:00:00Z

Eli Lilly is buying Centessa Pharmaceuticals, a developer of treatments for sleep-wake disorders, for US$38 per share in cash plus a contingent value right of up to US$9, up to US$7.8bn in total (Pharmaceutical Executive, 31 March 2026). Update (24 June 2026): the acquisition has been completed (SEC filing via edgar.tools, 24 June 2026). — Sources: https://www.pharmexec.com/view/eli-lilly-enters-7-billion-agreement-acquire-centessa-pharmaceuticals-advance-sleep-wake-treatments · https://app.edgar.tools/news/1d4c5a6fe477a225

tag:eurotrack.ai,2026:207a8891:en 2026-01-29T06:00:00Z

The pharmaceutical service provider for injectable medicines is building a new production site in Saarland. Construction start in Q2 2026, operations from 2031; up to 2,000 jobs possible in the long term. — Source: https://www.businesswire.com/news/home/20260129831882/en/Pharmaceutical-Service-Provider-Vetter-Pharma-to-Build-New-Manufacturing-Site-in-Germany

tag:eurotrack.ai,2026:35e89386:en 2025-12-31T06:00:00Z

Closure of the vaccine factory. Development of the Expec vaccine failed; production of lentiviral vector vaccines will be relocated to Sassenheim (Netherlands). — Source: https://www.bernerzeitung.ch/bern-buempliz-janssen-schliesst-impfstofffabrik-300-verlieren-job-967514550590

tag:eurotrack.ai,2026:6c455bcc:en 2025-12-10T06:00:00Z

Pfizer plans to reduce its Swiss workforce from 300 to 70 employees (230 jobs). The Zug branch had already been reduced from 200 to 131 in summer 2024 (69 dismissals). The current round of cuts is part of the global cost-saving programme; the affected sites (Opfikon ZH, Zug) remain unclear. The Swiss branch is classified as less important. — Source: https://www.zentralplus.ch/wirtschaft/muessen-zuger-pfizer-angestellte-zittern-2826671/

tag:eurotrack.ai,2026:264a6278:en 2025-12-09T06:00:00Z

Canada's Cronos Group announced on 9 December 2025 the purchase of Voorne aan Zee-based CanAdelaar, the largest operator in the Dutch adult-use cannabis pilot; the base price is €57.5m, plus contingent payments of 0.5 times normalised EBITDA for 2026 and 2027. Update (15 October 2026): the acquisition has been completed; CanAdelaar operates a greenhouse of about 50,000 m² (Cronos Group, 15 October 2026). — Source: https://www.globenewswire.com/news-release/2026/10/15/3381478/0/en/cronos-completes-acquisition-of-canadelaar-europe-s-largest-adult-use-cannabis-company.html

tag:eurotrack.ai,2026:27b16f63:en 2025-11-25T06:00:00Z

CureVac shareholders voted with over 99% in favour of the takeover by BioNTech. The exchange offer runs until 3 December 2025, with CureVac shares being exchanged for BioNTech ADS. Antitrust approval is in place. CureVac will be delisted and integrated into BioNTech. The open legal dispute with Pfizer/BioNTech was suspended. Update (18.12.2025): BioNTech closed its acquisition of CureVac on 18.12.2025; the compulsory acquisition of the remaining shares and the end of trading in CureVac shares were scheduled for January 2026 as part of the post-offer reorganisation (BioNTech press release via BioSpace, 18.12.2025). — Source: https://www.msn.com/de-de/finanzen/top-stories/fusion-mit-biontech-curevac-aktion%C3%A4re-haben-entschieden-so-reagieren-die-aktien/ar-AA1RaVjE

tag:eurotrack.ai,2026:e31c8ce6:en 2025-11-20T06:00:00Z

Novartis is gradually relocating the production of tablets and capsules at its Stein site by the end of 2027 and cutting around 550 jobs (about one in three jobs at the plant); a worldwide realignment of production networks, with a social plan planned. — Source: https://www.srf.ch/news/schweiz/stellenabbau-bei-pharmakonzern-novartis-streicht-550-stellen-in-stein-ag

tag:eurotrack.ai,2026:59349f3f:en 2025-10-22T06:00:00Z

BioNTech is launching a public exchange offer for the full takeover of CureVac; the all-stock deal values CureVac at around $1.25 billion. Update (6 January 2026): The takeover is complete — after the exchange offer, BioNTech took over all remaining CureVac shares through a post-offer reorganisation and is now the sole owner; Nasdaq trading was suspended on 6 January 2026 and the delisting took effect on 16 January 2026 (Panabee, 6 January 2026). — Source: https://www.biontech.com/int/en/home/mediaroom/news/press-releases/2025/10/biontech-commences-public-exchange-offer-all-outstanding-shares.html

tag:eurotrack.ai,2026:f9d5c802:en 2025-10-07T06:00:00Z

The Swiss-based pharmaceutical group Ferring has announced the cutting of up to 500 jobs worldwide in order to sharpen its focus and reduce costs. — Source: https://www.fiercepharma.com/pharma/ferring-reduce-staff-500-part-reorganization

tag:eurotrack.ai,2026:046f7e5c:en 2025-08-10T06:00:00Z

US pharmaceutical company Eli Lilly is building a new €2.3 bn production facility in Alzey for diabetes and obesity medications (incl. Mounjaro), operational from late 2027. In June 2026 Lilly announced it would halve the investment to around €1.15 bn over Germany's planned health-insurance reform — creating only about 500 jobs instead of 1,000. — Source: https://www.process.vogel.de/eli-lilly-investition-neue-produktionsstaette-alzey-a-04a6fa156daa6a4384c3e0ff308318bf/